Haisco and AbbVie (NYSE: ABBV) entered into an exclusive licensing agreement announced on April 10, 2026, which includes several pain candidates. Haisco granted AbbVie worldwide development, manufacturing, and commercialization rights, excluding mainland China, Hong Kong, and Macau. Haisco will receive an upfront payment of USD $30 million, milestones of up to USD $715 million, and tiered royalties on future net sales.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.